Cargando…

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development

Background: mRNA-based cancer vaccines have been considered a promising anticancer therapeutic approach against various cancers, yet their efficacy for malignant mesothelioma (MESO) is still not clear. The present study is designed to identify MESO antigens that have the potential for mRNA vaccine d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuhang, Yang, Yuqi, Li, Lu, Ma, Peiwen, Jiang, Yale, Ge, Minghui, Yu, Yue, Huang, Huiyao, Fang, Yuan, Jiang, Ning, Miao, Huilei, Guo, Hao, Yan, Linlin, Ren, Yong, Sun, Lichao, Zha, Yan, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331978/ https://www.ncbi.nlm.nih.gov/pubmed/35893817 http://dx.doi.org/10.3390/vaccines10081168

Ejemplares similares

Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
por: Wang, Shuhang, et al.
Publicado: (2022)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Seven-year exclusivity and beyond for drugs of rare diseases in China
por: Jiang, Yale, et al.
Publicado: (2023)

Targeting rare tumors: new focus for clinical research in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022)

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
por: Wang, Shuhang, et al.
Publicado: (2022)

CAR-macrophage: An extensive immune enhancer to fight cancer
por: Wang, Shuhang, et al.
Publicado: (2022)

Microfluidic cell squeeze-based vaccine comes into clinical investigation
por: Wang, Shuhang, et al.
Publicado: (2023)

Evolution of Early-Phase Anticancer Drug Investigations in China
por: Wang, Shuhang, et al.
Publicado: (2022)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development
por: Chen, Yan, et al.
Publicado: (2022)

Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
por: Zhang, Shichao, et al.
Publicado: (2022)

The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
por: Huang, Huiyao, et al.
Publicado: (2022)

Identification of tumor antigens in malignant mesothelioma
por: Kim, Ye-Rin, et al.
Publicado: (2017)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas
por: Mlika, Mona, et al.
Publicado: (2021)

Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma
por: Saddozai, Umair Ali Khan, et al.
Publicado: (2022)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development
por: Li, Ruo Qi, et al.
Publicado: (2022)

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach
por: Zhou, Jiawei, et al.
Publicado: (2023)

Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
por: Chen, Zhuohui, et al.
Publicado: (2022)

Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma
por: Zhou, Quanwei, et al.
Publicado: (2021)

Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype
por: Giusti, Laura, et al.
Publicado: (2016)

Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
por: Sejben, Anita, et al.
Publicado: (2023)

Outcome measures of phase III anticancer drug trials in China
por: Guo, Lanwei, et al.
Publicado: (2023)

Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma
por: Zhang, Chengke, et al.
Publicado: (2018)

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping
por: Di Stefano, Iosè, et al.
Publicado: (2023)

Rab27a Was Identified as a Prognostic Biomaker by mRNA Profiling, Correlated with Malignant Progression and Subtype Preference in Gliomas
por: Wang, Hongjun, et al.
Publicado: (2014)

Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma
por: Zhao, Deze, et al.
Publicado: (2022)

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
por: Zhong, Hua, et al.
Publicado: (2021)

Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
por: Lam, Sze-Kwan, et al.
Publicado: (2017)

HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
por: Wang, Yanbin, et al.
Publicado: (2019)

Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States
por: Huang, Huiyao, et al.
Publicado: (2022)

Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development
por: Wang, Zhi-liang, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development
por: Lu, Tai-Liang, et al.
Publicado: (2023)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Malignant mesothelioma
por: Moore, Alastair J, et al.
Publicado: (2008)

Malignant mesothelioma
por: Ahmed, Ishtiaq, et al.
Publicado: (2013)

Malignant Mesothelioma
por: Pouliquen, Daniel L., et al.
Publicado: (2021)

Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development
por: Liao, Weiran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mq72okj64t4s93905t5kr31brd